Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ann Thorac Surg ; 64(3): 826-9, 1997 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-9307481

RESUMO

BACKGROUND: Acute lung injury is associated with pulmonary hypertension, intrapulmonary shunting, and increased microvascular permeability, leading to altered oxygenation capacity. Thromboxane A2 has been found to be a central mediator in the development of septic and oleic acid (OA)-induced acute lung injury. Our previous study demonstrated a beneficial effect of preinjury thromboxane A2 receptor blockade. The current study examines the efficacy of postinjury receptor blockade on oxygenation capacity and pulmonary hemodynamics in an isolated lung model of OA-induced acute lung injury. METHODS: Four groups of rabbit heart-lung preparations were studied for 60 minutes in an ex vivo perfusion-ventilation system. Saline control lungs received saline solution during the first 20 minutes of study. Injury control lungs received an OA-ethanol solution during the first 20 minutes. Two treatment groups were used: T10, in which the thromboxane receptor antagonist, SQ30741, was infused 10 minutes after the initiation of OA infusion; and T30, in which the thromboxane receptor antagonist was infused 30 minutes after OA infusion. RESULTS: Significant differences were found in oxygenation (oxygen tension in T10 = 62.6 +/- 11.7 mm Hg, T30 = 68.2 +/- 21.2 mm Hg; injury control = 40.2 +/- 9.0 mm Hg, saline control = 123.5 +/- 16.01 mm Hg; p < 0.001) and percentile change in pulmonary artery pressure (T10 = 1.1% +/- 19.4% increase, T30 = 11.2% +/- 7.3% increase; injury control = 47.6% +/- 20.5%, saline control = 4.2% +/- 6.81%; p < 0.001). CONCLUSIONS: This study demonstrates that blockade of the thromboxane A2 receptor, even after the initiation of acute lung injury, eliminates pulmonary hypertension and improves oxygenation.


Assuntos
Fibrinolíticos/uso terapêutico , Receptores de Tromboxanos/antagonistas & inibidores , Síndrome do Desconforto Respiratório/prevenção & controle , Tromboxano A2/análogos & derivados , Animais , Infecções Bacterianas , Pressão Sanguínea/efeitos dos fármacos , Permeabilidade Capilar/efeitos dos fármacos , Modelos Animais de Doenças , Etanol/efeitos adversos , Fibrinolíticos/administração & dosagem , Hipertensão Pulmonar/complicações , Hipertensão Pulmonar/prevenção & controle , Infusões Intravenosas , Microcirculação/efeitos dos fármacos , Ácido Oleico/efeitos adversos , Oxigênio/sangue , Artéria Pulmonar , Circulação Pulmonar/efeitos dos fármacos , Coelhos , Tromboxano A2/administração & dosagem , Tromboxano A2/uso terapêutico , Volume de Ventilação Pulmonar/efeitos dos fármacos , Fatores de Tempo , Relação Ventilação-Perfusão/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...